文献速递炎症性肠病

血清三碘甲状腺原氨酸与甲状腺素比值(T3/T4)可预测老年炎症性肠病患者生物制剂的治疗结局

Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients.
PubMed 文献 · Aliment Pharmacol Ther · 2020-11-18

研究纳入80例60岁以上开始生物制剂治疗的炎症性肠病患者,评估基线T3/T4比值与54周时黏膜愈合和临床缓解的关系。基线T3/T4比值在黏膜愈合者中更高(每增加1单位OR 6.4 [2.9-14.3],P<0.0001),最佳阈值3.3预测黏膜愈合的敏感度78%、特异度89%(AUC 0.88 [0.79-0.94])。结论认为T3/T4比值似乎可作为预测老年IBD患者生物制剂治疗结局的可靠工具,若经验证可建议在开始生物治疗前评估。

要点

  • 基线T3/T4比值在黏膜愈合者中更高,每增加1单位OR 6.4(2.9-14.3),P<0.0001。
  • 基线T3/T4比值3.3为预测黏膜愈合最佳阈值,敏感度78%、特异度89%。
  • 结论认为T3/T4比值似乎是预测老年IBD生物制剂治疗结局的可靠工具。

核心结论

  • T3/T4比值似乎是预测老年IBD患者生物制剂治疗结局的可靠工具。
  • 若经验证,可建议在开始生物治疗前评估该参数。

研究设计与样本

  • 纳入60岁以上开始生物制剂治疗的IBD患者,共80例。
  • 治疗54周后评估黏膜愈合(溃疡性结肠炎Mayo内镜评分<2;克罗恩病溃疡消失)和临床缓解(溃疡性结肠炎部分Mayo评分<2;克罗恩病Harvey-Bradshaw指数<5)。
  • 基线T3/T4比值与治疗结局的关联采用多变量逻辑回归和受试者工作特征(ROC)曲线分析。

主要发现

  • 80例中44例达到临床缓解,36例达到黏膜愈合。
  • 基线T3/T4比值在黏膜愈合者中高于无黏膜愈合者(P<0.0001),且不受疾病类型或生物制剂种类影响。

关键数值与推荐

  • 基线T3/T4比值预测黏膜愈合的最佳阈值为3.3,敏感度78%、特异度89%。

临床怎么用

  • 原文结论认为T3/T4比值似乎是预测老年IBD患者生物制剂治疗结局的可靠工具。
  • 作者认为若经验证,可建议在开始生物治疗前评估该参数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Rates of elderly patients with inflammatory bowel diseases (IBDs) are increasing, and biomarkers are needed to optimise their therapies. Serum triiodothyronine-to-thyroxine (T3/T4) ratio has been correlated with geriatric patient frailty. AIM: To assess the suitability of T3/T4 ratio as a response marker to biologics in elderly patients with IBD. METHODS: Patients with IBD over 60 years old were enrolled, when starting biological therapy. Therapeutic outcome was assessed after 54 weeks of treatment as mucosal healing (Mayo endoscopic score < 2 for ulcerative colitis; ulcer disappearance for Crohn's disease) and clinical remission (Partial Mayo Score < 2 for ulcerative colitis; Harvey-Bradshaw Index < 5 for Crohn's disease). T3/T4 ratio was evaluated at baseline, and its association with therapeutic outcomes was tested by multivariable logistic regression and receiver operating characteristic (ROC). RESULTS: We enrolled 80 patients; 44 achieved clinical remission and 36 mucosal healing. Baseline T3/T4 ratio was higher in patients with mucosal healing, as compared with those without mucosal healing (P < 0.0001), regardless of the disease type or biological drug (OR 6.4 [2.9-14.3] for each T3/T4 unit increase, P < 0.0001). A cut point of 3.3 was identified as the optimal threshold of baseline T3/T4 ratio for predicting mucosal healing, providing 78% sensitivity and 89% specificity (area under the ROC curve 0.88 [0.79-0.94]; positive and negative likelihood ratios 6.8 [2.9-15.9] and 0.3 [0.1-0.5] respectively). CONCLUSIONS: T3/T4 ratio seems a reliable tool for predicting therapeutic outcome of biological therapy in elderly patients with IBD. If validated, the assessment of this parameter before starting biological treatment might be suggested.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bertani L, Tricò D, Pugliese D, et al. Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients. Aliment Pharmacol Ther. 2020. PMID: 33210332. doi:10.1111/apt.16167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。